Centre for Human Drug Research, Netherlands

Quick facts

Marketed products

• Clindamycin 1% topical lotion formulation
• Erythromycin 4% topical gel formulation

Phase 1 pipeline

• Adalimumab ID · Immunology
  Tumour necrosis factor-alpha inhibitor
• Adalimumab SC · Immunology
  Tumour necrosis factor-alpha inhibitor
• Clindamycin 1% lotion formulation:

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Centre for Human Drug Research, Netherlands portfolio CI brief
• Centre for Human Drug Research, Netherlands pipeline updates RSS